Related Experiment Video
Updated: Sep 11, 2025

Purification and microRNA Profiling of Exosomes Derived from Blood and Culture Media
Published on: June 14, 2013
Exploring the bioactivity of MicroRNAs Originated from Plant-derived Exosome-like Nanoparticles (PELNs): current
Kingsley Miyanda Tembo1,2, Xiaohui Wang1, Mansoor Bolideei1,3
1The Center for Biomedical Research, Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, Wuhan, China.
None:
Exosomes, nano-sized extracellular vesicles, facilitate intercellular communication by transferring biomolecules such as microRNAs (miRNAs), which are key regulators of gene expression. While mammalian-derived exosomes (MDEs) have shown therapeutic promise, their clinical application has been limited by challenges such as immune-related toxicities, low yield and high production costs. In contrast, plant-derived exosome-like nanoparticles (PELNs) offer a sustainable, biocompatible, and cost-effective alternative, encapsulating a diverse array of bioactive miRNAs with significant therapeutic potential. Studies have demonstrated the ability of PELN-derived miRNAs in cross-kingdom communication, effectively transferring into mammalian cells, where they modulate disease-related pathways, including cancer, inflammation, metabolism, and neurodegeneration. This review explores the bioactivity of plant-derived miRNAs, highlighting their role as novel therapeutic agents. The study explores the bioactivity and potential mechanisms by which these miRNAs influence human cellular processes, focusing on their ability to regulate gene expression in different tissues. Additionally, the study examines recent advances in PELN research, emphasizing their potential for clinical translation in precision medicine, and highlights challenges and future prospects in harnessing the therapeutic capabilities of these bioactive miRNAs. This review underscores the potential of PELNs to revolutionize therapeutic strategies, offering a sustainable, biocompatible, and cost-effective platform for targeted miRNA delivery, paving the way for innovative interventions leveraging nature's own nanocarriers.
More Related Videos
09:30Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes
Published on: May 24, 2019
08:34Author Spotlight: Peptidome Extraction from Small Extracellular Vesicles Isolated from Bone Marrow-Derived Macrophages
Published on: June 30, 2023
Related Concept Videos
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
MicroRNAs